An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment.

Trial Profile

An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Fenofibrate (Primary) ; Pioglitazone (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Status changed from recruiting to completed.
    • 21 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top